BioLineRx and Hemispherian Announce First Patient Dosed in Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. MU
4. SPY
5. ACN
6. IBM
7. META
8. PFE
9. TSLA
10. DPZ

Go back to BioLineRx and Hemispherian Announce First Patient Dosed in Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)
BIOLINE RX SP ADR (NASDAQ: BLRX) Delayed: 3.34 +0.10 (3.09%)
Previous Close $3.24    52 Week High $1.63 
Open $3.23    52 Week Low $0.71 
Day High $3.45    P/E N/A 
Day Low $3.23    EPS $0.00 
Volume 71,375       

BIOLINE RX SP ADR (NASDAQ: BLRX) Delayed: 3.34 +0.10 (3.09%)
Previous Close $3.24    52 Week High $1.63 
Open $3.23    52 Week Low $0.71 
Day High $3.45    P/E N/A 
Day Low $3.23    EPS $0.00 
Volume 71,375